1998
DOI: 10.1016/s0022-510x(98)00102-6
|View full text |Cite
|
Sign up to set email alerts
|

Dopaminergic influences on the P300 abnormality in Parkinson's disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
32
0

Year Published

2001
2001
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 44 publications
(36 citation statements)
references
References 33 publications
(13 reference statements)
4
32
0
Order By: Relevance
“…P300 studies on PD patients have shown that P300 latency is prolonged (6,(12)(13)(14)(15)(16). Similar to the previous studies, we found that P300 latency was prolonged in PD patients compared to the control group (Table 2).…”
Section: Discussionsupporting
confidence: 90%
“…P300 studies on PD patients have shown that P300 latency is prolonged (6,(12)(13)(14)(15)(16). Similar to the previous studies, we found that P300 latency was prolonged in PD patients compared to the control group (Table 2).…”
Section: Discussionsupporting
confidence: 90%
“…In most of the studies on levodopa effects, nevermedicated PD patients or patients who underwent a drug washout period (12 h -14 days) were tested on an oddball procedure, first off and then on medication. We identified nine studies employing such a study design with five of them demonstrating a reduction of P3b latency following levodopa administration (Lukhanina et al, 2009;Oishi et al, 1996;Sohn et al, 1998;Stanzione et al, 1991;Starkstein et al, 1989). However, P3b latency was not significantly decreased by levodopa in the studies by Chia et al (1995), Kobayashi et al (2004), and Mathis et al (2014) and even increased under levodopa in the study by Prasher and Findley (1991).…”
Section: P3b and Dopaminergic Medication In Pdmentioning
confidence: 99%
“…Since dopaminergic function is an important determinant for P300 components [4,6] and evidence suggests a relationship between genetic effects and P300 components [7,8], several studies have investigated the association between the dopamine D2 receptor (DRD2) genetic polymorphism and P300. In 1994, Noble et al [9], first demonstrated relatively prolonged P300 latency for boys bearing the A1 allele of the DRD2 TaqI A polymorphism in comparison to A2-allele analogs.…”
Section: Introductionmentioning
confidence: 99%